Dr. Adeel Khan

Shouldn't everyone be doing this? But it turns out when you make that old cell young again, it makes it almost embryonic in nature, which means it can cause cancer or tumors. So IPSCs, as they're called, or Yamanaka stem cells to honor Professor Yamanaka, they're great. But the problem is they have the risk of tumor genicity. And so we don't actually use them clinically yet.

Shouldn't everyone be doing this? But it turns out when you make that old cell young again, it makes it almost embryonic in nature, which means it can cause cancer or tumors. So IPSCs, as they're called, or Yamanaka stem cells to honor Professor Yamanaka, they're great. But the problem is they have the risk of tumor genicity. And so we don't actually use them clinically yet.

uh there's a lot of work being done on it but it's still i think a few years away from clinical translation so that's why the new cells because we know they don't cause cancer and we know they're naturally occurring on the body so they have a lot more clinical translation than the yamanaka steps

uh there's a lot of work being done on it but it's still i think a few years away from clinical translation so that's why the new cells because we know they don't cause cancer and we know they're naturally occurring on the body so they have a lot more clinical translation than the yamanaka steps

Yeah, so about 10 to 15 times more are able to go into circulation. So there is still some that get trapped in the lungs, but Professor Dazao has shown work showing that it's, you know, it's not like two times more. We're talking an order of magnitude, like 10 times more are able to go into circulation. So it is still a big difference compared to standard MSCs.

Yeah, so about 10 to 15 times more are able to go into circulation. So there is still some that get trapped in the lungs, but Professor Dazao has shown work showing that it's, you know, it's not like two times more. We're talking an order of magnitude, like 10 times more are able to go into circulation. So it is still a big difference compared to standard MSCs.

Yeah, look, I just had an ALS patient I treated a couple of weeks ago and I was blown away because it was my first ALS patient I treated with new cells and she couldn't swallow because of the bulbar symptoms, you know, and now she can swallow. She can speak clearly. She was barely able to speak before. And that was just one IV. And I mean, it was pretty incredible to see.

Yeah, look, I just had an ALS patient I treated a couple of weeks ago and I was blown away because it was my first ALS patient I treated with new cells and she couldn't swallow because of the bulbar symptoms, you know, and now she can swallow. She can speak clearly. She was barely able to speak before. And that was just one IV. And I mean, it was pretty incredible to see.

Obviously, that's anecdotal, but the clinical trial that was done also showed, you know, some slowing of progression there. And we all know how devastating ALS is. And if there's something that can slow it down even, I think we just don't know the exact dosing for ALS yet. But I think for now, I think we can certainly say it can be helpful and it's not harmful.

Obviously, that's anecdotal, but the clinical trial that was done also showed, you know, some slowing of progression there. And we all know how devastating ALS is. And if there's something that can slow it down even, I think we just don't know the exact dosing for ALS yet. But I think for now, I think we can certainly say it can be helpful and it's not harmful.

And then for stroke, we can be much more kind of certain that they are going to have positive results because in stroke, for example, she showed that 30% of patients in the clinical trial were able to go back to full-time work when they were disabled. Like we're talking patients who are disabled.

And then for stroke, we can be much more kind of certain that they are going to have positive results because in stroke, for example, she showed that 30% of patients in the clinical trial were able to go back to full-time work when they were disabled. Like we're talking patients who are disabled.

And they're able to go back. Yeah, exactly. And they go back to full-time work. So now 30% of people and the other 70% still had significant clinical benefits and were able to get off. You know, we're- They weren't necessarily able to return to work, but a lot of them were able to get back to normal functioning of ADLs and IADLs and stuff like that, which is still a big deal.

And they're able to go back. Yeah, exactly. And they go back to full-time work. So now 30% of people and the other 70% still had significant clinical benefits and were able to get off. You know, we're- They weren't necessarily able to return to work, but a lot of them were able to get back to normal functioning of ADLs and IADLs and stuff like that, which is still a big deal.

And you know what the most interesting part was? 25% of the patients in the clinical trial had reversal of gray hair. And that was just like an accidental finding.

And you know what the most interesting part was? 25% of the patients in the clinical trial had reversal of gray hair. And that was just like an accidental finding.

Yeah, well, I mean, I know it sounds, you almost sound like a used car salesman or something when you're like, this can treat everything, you know? But once you understand the physiology of chronic disease, as you do, you understand that there's certain hallmarks of aging and there's hallmarks of chronic disease that overlap.

Yeah, well, I mean, I know it sounds, you almost sound like a used car salesman or something when you're like, this can treat everything, you know? But once you understand the physiology of chronic disease, as you do, you understand that there's certain hallmarks of aging and there's hallmarks of chronic disease that overlap.

So I'm not going to list all 12 of them because I'll bore people, but there's basically 12 hallmarks of aging. We've listed a few of them, mitochondrial dysfunction, you know, stem cell exhaustion. Yeah. Chronic inflammation, which is related to amino senescence. And, you know, there's lots of protein, like there's so many protein misfolding. There's so many other ones.

So I'm not going to list all 12 of them because I'll bore people, but there's basically 12 hallmarks of aging. We've listed a few of them, mitochondrial dysfunction, you know, stem cell exhaustion. Yeah. Chronic inflammation, which is related to amino senescence. And, you know, there's lots of protein, like there's so many protein misfolding. There's so many other ones.